Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial

• Published in: JNCI : Journal of the National Cancer Institute Vol. 102; no. 24; pp. 1835 - 1844
• Main Authors: Elmets, Craig A., Viner, Jaye L., Pentland, Alice P., Cantrell, Wendy, Lin, Hui-Yi, Bailey, Howard, Kang, Sewon, Linden, Kenneth G., Heffernan, Michael, Duvic, Madeleine, Richmond, Ellen, Elewski, Boni E., Umar, Asad, Bell, Walter, Gordon, Gary B.
• Format: Journal Article
• Language: English
• Published: Cary, NC Oxford University Press 15.12.2010; Oxford Publishing Limited (England)
• Subjects: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents - administration & dosage; Anticarcinogenic Agents - adverse effects; Anticarcinogenic Agents - therapeutic use; Biological and medical sciences; Carcinoma, Basal Cell - prevention & control; Carcinoma, Squamous Cell - prevention & control; Celecoxib; Cell Transformation, Neoplastic; Chemotherapy; Clinical trials; Cyclooxygenase 2 Inhibitors - therapeutic use; Dermatology; Double-Blind Method; Female; Humans; Inhibitor drugs; Keratosis, Actinic - drug therapy; Keratosis, Actinic - pathology; Male; Medical sciences; Middle Aged; Oncology; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrazoles - therapeutic use; Skin cancer; Skin Neoplasms - etiology; Skin Neoplasms - prevention & control; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Sulfonamides - therapeutic use; Treatment Outcome; Tumors; Tumors of the skin and soft tissue. Premalignant lesions; United States; North America; America; Human; Prostaglandin-endoperoxide synthase; Skin disease; Chemoprophylaxis; Enzyme; Enzyme inhibitor; Cyclooxygenase 2 inhibitor; Malignant tumor; Celecoxib; Randomized controlled trial; Skin cancer; Prevention; Cancerology; Double blind study; Oxidoreductases; Public health; Cancer

Background Preclinical studies indicate that the enzyme cyclooxygenase 2 plays an important role in ultraviolet-induced skin cancers. We evaluated the efficacy and safety of celecoxib, a cyclooxygenase 2 inhibitor, as a chemopreventive agent for actinic keratoses, the premalignant precursor of nonme...